CONTACT: A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Six-Month Safety and Efficacy Study of Dimebon in Patients With Moderate-to-Severe Alzheimer's Disease.

Trial Profile

CONTACT: A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Six-Month Safety and Efficacy Study of Dimebon in Patients With Moderate-to-Severe Alzheimer's Disease.

Discontinued
Phase of Trial: Phase III

Latest Information Update: 29 Sep 2016

At a glance

  • Drugs Latrepirdine (Primary)
  • Indications Alzheimer's disease
  • Focus Pharmacogenomic; Registrational; Therapeutic Use
  • Acronyms CONTACT
  • Most Recent Events

    • 26 Sep 2012 Waiting for a couple of endpoints to be added to Thes
    • 31 Aug 2010 Status changed from suspended to discontinued as reported by ClinicalTrials.gov.
    • 10 May 2010 Status changed from recruiting to suspended, according to a Medivation media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top